News

A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA, Darmstadt, Germany’s

The regulator issued a complete response letter (CRL) over the chemistry, manufacturing and controls (CMC) prior-approval supplement (PAS) for the Eylea pre-filled syringe. Eylea injection is a vascular

AF affects approximately 350,000 patients in Canada. St. Michael’s Hospital staff cardiac electrophysiologist and University of Toronto cardiology division department director Dr Paul Dorian said: “Brinavess offers an important

An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. The agreement provides

Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to

In the pharmaceutical industry, clinical-trial data is of paramount importance for drug development, and must be backed up and protected against any potential mishaps. Therefore, a Hybrid Cloud

The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic

Ci:z is engaged in the development, marketing and distribution of a range of dermocosmetic, cosmetic and skincare products. As per terms of the deal, J&J and its affiliates

Cerevel Therapeutics has secured $350m funding from funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences. They have also committed to provide further capital if